These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 7018790

  • 1. Triamterene-thiazide combination: alternative therapy for primary aldosteronism.
    Ganguly A, Weinberger MH.
    Clin Pharmacol Ther; 1981 Aug; 30(2):246-50. PubMed ID: 7018790
    [Abstract] [Full Text] [Related]

  • 2. Long-term medical management of aldosterone-producing adenoma.
    Bornemann M.
    South Med J; 1990 Apr; 83(4):461-2. PubMed ID: 2108504
    [Abstract] [Full Text] [Related]

  • 3. Primary aldosteronism: effects of inhibition of ACTH and potassium administration on plasma aldosterone concentration.
    Ganguly A, Luetscher JA, Weinberger MH.
    Clin Exp Hypertens A; 1982 Apr; 4(9-10):1695-714. PubMed ID: 6291813
    [Abstract] [Full Text] [Related]

  • 4. [Properties and indications of potassium-sparing diuretics].
    Rorive G, Krzesinski JM.
    Rev Med Liege; 1986 May 01; 41(9):330-6. PubMed ID: 3523669
    [No Abstract] [Full Text] [Related]

  • 5. Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension.
    Jeunemaitre X, Charru A, Chatellier G, Degoulet P, Julien J, Plouin PF, Corvol P, Ménard J.
    Am J Cardiol; 1988 Nov 15; 62(16):1072-7. PubMed ID: 3189169
    [Abstract] [Full Text] [Related]

  • 6. Differing effects of mineralocorticoid receptor-dependent and -independent potassium-sparing diuretics on fibrinolytic balance.
    Ma J, Albornoz F, Yu C, Byrne DW, Vaughan DE, Brown NJ.
    Hypertension; 2005 Aug 15; 46(2):313-20. PubMed ID: 15998706
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. PRIMARY ALDOSTERONISM AND THE EFFECTS OF TWO MINERALOCORTICOID INHIBITORS--TRIAMTERENE AND SPIRONOLACTONE (ALDACTONE).
    ROBERTSON GL, DAWSON JW.
    Can Med Assoc J; 1964 May 16; 90(20):1170-3. PubMed ID: 14145473
    [No Abstract] [Full Text] [Related]

  • 17. [The effect of bemetizide-triamterene on the serum and whole body potassium in hypertensive patients (author's transl)].
    Schäfer GE, Werner E.
    MMW Munch Med Wochenschr; 1978 Nov 10; 120(45):1505-7. PubMed ID: 101820
    [Abstract] [Full Text] [Related]

  • 18. Spironolactone and triamterene in volume-dependent essential hypertension.
    DeCarvalho JG, Emery AC, Frohlich ED.
    Clin Pharmacol Ther; 1980 Jan 10; 27(1):53-6. PubMed ID: 6985854
    [Abstract] [Full Text] [Related]

  • 19. The absence of long-term therapeutic effect of calcium channel blockade in the primary aldosteronism of adrenal adenomas.
    Bursztyn M, Grossman E, Rosenthal T.
    Am J Hypertens; 1988 Jul 10; 1(3 Pt 3):88S-90S. PubMed ID: 3046636
    [Abstract] [Full Text] [Related]

  • 20. Time-related changes in plasma adrenal steroids during treatment with spironolactone in primary aldosteronism.
    Sakamoto H, Ichikawa S, Sakamaki T, Nakamura T, Ono Z, Takayama Y, Murata K.
    Am J Hypertens; 1990 Jul 10; 3(7):533-7. PubMed ID: 2194510
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.